Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
SAMDAILY.US - ISSUE OF MAY 09, 2024 SAM #8199
SPECIAL NOTICE

J -- NMRC Bone Marrow Program

Notice Date
5/7/2024 8:24:58 AM
 
Notice Type
Special Notice
 
NAICS
621511 — Medical Laboratories
 
Contracting Office
NAVAL MEDICAL RESEARCH CENTER SILVER SPRING MD 20910-7500 USA
 
ZIP Code
20910-7500
 
Solicitation Number
N3239824Q9982
 
Response Due
5/22/2024 9:00:00 AM
 
Archive Date
06/06/2024
 
Point of Contact
Shamai M. Carter, Phone: 3013197182, Deborah M. Sharpe, Phone: 3013196471
 
E-Mail Address
shamai.m.carter.civ@health.mil, deborah.m.sharpe2.civ@health.mil
(shamai.m.carter.civ@health.mil, deborah.m.sharpe2.civ@health.mil)
 
Description
The United States Department Of Naval Medical Research Command�(NMRC) intends to award a sole source contract, CareDX Lab Solutions.,�West Chester, PA. 19382. This notice is not a request for competitive�proposals however If interested Government shall consider all responses. The DoD Bone Marrow Program mission in the treatment of radiation and chemical weapon exposure is unique to the Armed Forces.�When prescribed 90% of drugs work only in 30-50% this is because 90% of individuals are likely to have different clinically actionable pharmacogenetic genotype.�There is a strong and well documented correlation between drug efficacy and variation in genes responsible for drug metabolism or transport (Pharmacogenetics; PGx).�Maintaining an optimal level of immunosuppression is critical for successful post-transplant management after HSCT. Too low level of immunosuppression might lead to GvHD and relapse, whereas too high level of immunosuppression might lead to toxicity and deleterious side effects. Metabolism and efficacy of most commonly used immunosuppressive drugs are modulated by pharmacogenes. Variations in pharmacogenes are widespread across different populations, with many of them frequent in minority groups. Genetic testing allows for identification of patients carrying deleterious variants in pharmacogenes. The proposed action is the continuation of research to develop an NGS-based assay using hybrid capture technology to assess response to various immunosuppression protocols (drugs) in the surveillance of HSCT patients. 1. Stage 1 Optimization Personnel Hours 2. Stage 1 Optimization Reagents Cost 3. Stage 2 Verification Personnel Hours 4. Stage 2 Verification Reagents Cost 5. Stage 3 Software Development - Initiation phase Personnel hours Period Of Performance Sep 2024 - May 2025. The NAICS code for this action is 621511. This requirement will be procured under the guidelines of FAR Part 12 Commercial Items. NMRC requires that all contractors doing business with the Acquisition Office must be registered with the Systems for Award Management (SAM). No award can be made unless the vendor is registered in Systems for Award Management. For additional information and to register in SAM, please access the following website: https://www.sam.gov/. In order to register with the SAM and to be eligible to receive an award from this Acquisition Office, all offers must have a Unique Entity Identification Number (UEI). A Sam.gov number may be acquired free of charge by contacting Sam.gov online at www.sam.gov or by phone at (866) 606-8220.� See attached J&A for specifics.� Email your Quote to the following: shamai.m.carter.civ@health.mil deborah.m.sharpe2.civ@health.mil �
 
Web Link
SAM.gov Permalink
(https://sam.gov/opp/4d39d4910f9342ab884a17da65073c2a/view)
 
Place of Performance
Address: Silver Spring, MD 20910, USA
Zip Code: 20910
Country: USA
 
Record
SN07055150-F 20240509/240507230043 (samdaily.us)
 
Source
SAM.gov Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.